Literature DB >> 12821500

In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin.

Lance B Price1, Amy Vogler, Talima Pearson, Joseph D Busch, James M Schupp, Paul Keim.   

Abstract

Mutants of attenuated Bacillus anthracis with high-level ciprofloxacin resistance were isolated using a three-step in vitro selection. Ciprofloxacin MICs were 0.5 micro g/ml for first-step mutants, which had one of two gyrA quinolone resistance-determining region (QRDR) mutations. Ciprofloxacin MICs were 8 and 16 microg/ml for second-step mutants, which had one of three parC QRDR mutations. Ciprofloxacin MICs for third-step mutants were 32 and 64 microg/ml. Mutants for which MICs were 64 microg/ml had one of two additional mutations within the gyrA QRDR or one of two mutations within the gyrB QRDR. Mutants for which MICs were 32 microg/ml had no additional target modifications but showed evidence of enhanced ciprofloxacin efflux.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12821500      PMCID： PMC161847          DOI： 10.1128/AAC.47.7.2362-2365.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Antibiotic susceptibilities of 96 isolates of Bacillus anthracis isolated in France between 1994 and 2000.

Authors:  Jean-Didier Cavallo; Francoise Ramisse; Monique Girardet; Josée Vaissaire; Michelle Mock; Eric Hernandez
Journal:  Antimicrob Agents Chemother       Date:  2002-07       Impact factor: 5.191

2.  In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones.

Authors:  I Brook; T B Elliott; H I Pryor; T E Sautter; B T Gnade; J H Thakar; G B Knudson
Journal:  Int J Antimicrob Agents       Date:  2001-12       Impact factor: 5.283

3.  Antimicrobial susceptibilities of diverse Bacillus anthracis isolates.

Authors:  Pamala R Coker; Kimothy L Smith; Martin E Hugh-Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

4.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

5.  The multidrug efflux transporter of Bacillus subtilis is a structural and functional homolog of the Staphylococcus NorA protein.

Authors:  A A Neyfakh
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

6.  Quinolone resistance mutations in topoisomerase IV: relationship to the flqA locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

7.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.

Authors:  A A Neyfakh; C M Borsch; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  [Comparison of therapeutic effects of antibiotics of the tetracycline group in the treatment of anthrax caused by a strain inheriting tet-gene of plasmid pBC16].

Authors:  A P Pomerantsev; N A Shishkova; L I Marinin
Journal:  Antibiot Khimioter       Date:  1992-04

Review 9.  Bacillus anthracis and antibacterial agents.

Authors:  A Bryskier
Journal:  Clin Microbiol Infect       Date:  2002-08       Impact factor: 8.067

10.  Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus.

Authors:  L Ferrero; B Cameron; J Crouzet
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191
View more
  55 in total

1.  Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.

Authors:  Katie J Aldred; Sylvia A McPherson; Pengfei Wang; Robert J Kerns; David E Graves; Charles L Turnbough; Neil Osheroff
Journal:  Biochemistry       Date:  2011-12-16       Impact factor: 3.162

2.  Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.

Authors:  Henry S Heine; Jennifer Bassett; Lynda Miller; Bret K Purcell; W Russell Byrne
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

3.  Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions.

Authors:  Katie J Aldred; Heidi A Schwanz; Gangqin Li; Sylvia A McPherson; Charles L Turnbough; Robert J Kerns; Neil Osheroff
Journal:  ACS Chem Biol       Date:  2013-09-30       Impact factor: 5.100

4.  Rapid polymerase chain reaction-based screening assay for bacterial biothreat agents.

Authors:  Samuel Yang; Richard E Rothman; Justin Hardick; Marcos Kuroki; Andrew Hardick; Vishal Doshi; Padmini Ramachandran; Charlotte A Gaydos
Journal:  Acad Emerg Med       Date:  2008-04       Impact factor: 3.451

Review 5.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

6.  A rapid antimicrobial susceptibility test for Bacillus anthracis.

Authors:  Linda M Weigel; David Sue; Pierre A Michel; Brandon Kitchel; Segaran P Pillai
Journal:  Antimicrob Agents Chemother       Date:  2010-05-03       Impact factor: 5.191

7.  Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.

Authors:  Suresh K Tipparaju; Debbie C Mulhearn; Gary M Klein; Yufeng Chen; Subhasish Tapadar; Molly H Bishop; Shuo Yang; Juan Chen; Mahmood Ghassemi; Bernard D Santarsiero; James L Cook; Mary Johlfs; Andrew D Mesecar; Michael E Johnson; Alan P Kozikowski
Journal:  ChemMedChem       Date:  2008-08       Impact factor: 3.466

8.  Rapid identification of genetic modifications in Bacillus anthracis using whole genome draft sequences generated by 454 pyrosequencing.

Authors:  Peter E Chen; Kristin M Willner; Amy Butani; Shakia Dorsey; Matroner George; Andrew Stewart; Shannon M Lentz; Christopher E Cook; Arya Akmal; Lance B Price; Paul S Keim; Alfred Mateczun; Trupti N Brahmbhatt; Kimberly A Bishop-Lilly; Michael E Zwick; Timothy D Read; Shanmuga Sozhamannan
Journal:  PLoS One       Date:  2010-08-25       Impact factor: 3.240

9.  Small molecule inhibitors of anthrax lethal factor toxin.

Authors:  John D Williams; Atiyya R Khan; Steven C Cardinale; Michelle M Butler; Terry L Bowlin; Norton P Peet
Journal:  Bioorg Med Chem       Date:  2013-11-13       Impact factor: 3.641

10.  Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.

Authors:  Patrick Grohs; Isabelle Podglajen; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.